Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, China.
Clin Infect Dis. 2015 Jan 15;60(2):275-8. doi: 10.1093/cid/ciu798. Epub 2014 Oct 13.
Lamivudine and tenofovir disoproxil fumarate (TDF) are both active against hepatitis B virus (HBV). Due to its potency, high genetic barrier to resistance, and safety during pregnancy, TDF may be useful to prevent HBV transmission from mother to child, which is the leading cause of transmission globally. Despite the safety record of lamivudine and TDF in pregnancy, the labels for both of these drugs recommend against their use during breastfeeding. In this review, we discuss the data regarding lamivudine and TDF use during pregnancy and breastfeeding and find that the exposure to the drug is lower from breastfeeding than from in utero exposure. Thus, the data do not support the contraindication to their use during breastfeeding.
拉米夫定和富马酸替诺福韦二吡呋酯（TDF）均对乙型肝炎病毒（HBV）具有活性。由于 TDF 具有效力高、耐药性遗传屏障高以及在妊娠期间安全的特点，TDF 可能有助于预防 HBV 从母亲传播给孩子，这是全球传播的主要原因。尽管拉米夫定和 TDF 在妊娠期间的安全性记录良好，但这两种药物的标签都建议不要在哺乳期使用。在这篇综述中，我们讨论了关于拉米夫定和 TDF 在妊娠和哺乳期使用的数据，发现从母乳喂养中接触到的药物比从宫内暴露中接触到的药物要低。因此，这些数据不支持在哺乳期使用这些药物的禁忌。
